A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). This ...
GlobalData on MSN2d
Amgen opens new drug substance facility in North Carolina, USSituated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...
MedPage Today on MSN6d
New AGA Guideline; Imaging for HCC Surveillance; 'Breakthrough' Hepatitis D DrugResearchers identified the enzyme CMPK2 as a possible target for therapies aiming to prevent metabolic dysfunction-associated ...
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
The company previously received US Food and Drug Administration (FDA) approval for its LUMAKRAS (sotorasib) and Vectibix (panitumumab) combination therapy for treating adults with KRAS G12C ...
Dato-DXd for breast cancer and sotorasib/panitumumab for CRC have gained FDA approval and a new drug is under FDA review for BCG-unresponsive, high-risk NMIBC. We also explore the controversy ...
At the moment there are two KRAS inhibitors on the market, Krazati and Amgen’s Lumakras (sotorasib), which are ... combination with its own EGFR drug Vectibix (panitumumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback